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Enterococcus faecium is a ubiquitous bacterium that only recently emerged as a nosocomial multi-
resistant pathogen. Infections mostly affect immunocompromised patients and the high 
antimicrobial resistance of E. faecium often hampers treatment. To understand E. faecium’s 
pathogenicity research on virulence factors is needed. The focus of this thesis are features, which 
give pathogenic potential to E. faecium. First, TIR-domain-containing proteins (TirEs) are 
examined as immune evasion factors. Second, it is investigated if membrane vesicles (MVs) are 
produced by nosocomial E. faecium and whether they contain virulence-related cargo. Third, the 
content of a megaplasmid originating from a bacteremia isolate is characterized.  
TirE proteins are described as novel virulence factors of E. faecium. The tirE encoding genes are 
exclusive to nosocomial E. faecium strains and localized on a putative mobile genetic element of 
phage origin. Comparison of the wild-type and its isogenic mutant which lacks the tirE locus 
showed that the tirE locus promotes bacterial proliferation in human blood. Both TirE proteins were 
detected in bacterial supernatant and one of them was associated with membrane vesicles derived 
from E. faecium (Paper I). 
An isolation protocol using ultracentrifugation and purification of the vesicles over a density 
gradient was established. Using a proteomic approach the proteinaceous content of four different 
clinically relevant strains under two different growth conditions was described. In addition to 
virulence factors, the MVs were found to contain vaccine candidates and antimicrobial resistance 
related proteins. Thus, MVs are likely to be used by E. faecium to release virulence-promoting 
factors (Paper II).  
A putative virulence factor-encoding megaplasmid was transferred to a commensal strain by filter-
mating experiments. The megaplasmid enhanced the bacterial proliferation in a blood survival 
assay. DNA sequence analysis of the plasmid and its variants revealed candidate genes, which are 
potentially responsible for the observed effect. Most factors encoded by these candidate genes are 
predicted to be involved in primary metabolic processes and the genes are enriched among clinical 
strains. Megaplasmids are therefore likely to serve as vessels for various genes, including those 





	   	  
Introduction	  
Characteristics	  of	  E.	  faecium	  
General	  features	  of	  E.	  faecium	  
Enterococci are facultative anaerobic non-spore-forming Gram-positive bacteria of the phylum 
Firmicutes, and often occur in pairs as diplococci 1, as illustrated in figure 1. Enterococci reside in 
sand, fresh and marine water sediment, soil and vegetation, but also colonizes the gastrointestinal 
tract of mammals, birds, reptiles and insects 2. In humans enterococci make up less than 1% of the 
adult gut microbiota 3. The two most abundant enterococcal commensals of humans are 
Enterococcus faecium and Enterococcus faecalis 4. E. faecalis historically accounted for 80 to 90% 
of the clinical enterococcal isolates, whereas only 5 to 10% used to be E. faecium 5. Presently, 
however, E. faecium has risen to be the cause of more than 30% of enterococcal infections 6. 
 
Figure 1: Electron microscopy picture of E. faecium E155. E. faecium typically occurs as diplococci.  
 
The	  clade	  structure	  of	  E.	  faecium	  
A deep phylogenic split of the hospital-associated clade (A) and the commensal clade (B) 
characterizes the clade structure of E. faecium. First, MLST (multilocus sequence typing), where 
isolates are compared based on their allelic profile of seven housekeeping genes, suggested that 





	   	  
important lineages ST17, ST18, ST78) and clustered differently from community isolates 7. The 
relation of these STs (sequence types), based on the number of shared alleles, used to be assessed 
by eBURST 8. However, more recent analyses showed that the high recombination rate within E. 
faecium makes this analysis unreliable and that eBURST networks wrongly link unrelated CCs 9. 
The current method of choice is therefore BAPS (Bayesian Analysis of Population Structure), 
which uses a statistical genetic model to subdivide molecular variation based on clonal ancestry and 
recombination patterns 10. Here, E. faecium isolates cluster into numerous groups, but the majority 
of nosocomial isolates cluster into only two subgroups: 2-1, including the ST78 lineage, and 3-3, 
including the ST17 and ST18 lineages 10. 
Now it is known, that the nosocomial clade A1 and the commensal clade B split 3.000 years ago, a 
time that coincides with increasing urbanization, domestication of livestock and the introduction of 
hygiene measures 11. Clade A and B differ in core genome level at 3,2 – 4% 12. Approximately 75 
years ago, a split occurred within clade A. The hypermutating clade A1, including the majority of 
clinical E. faecium isolates, branched from clade A2, which mainly consists of animal isolates 11. 
Interestingly, this timeframe overlaps with the beginning of the modern antibiotic era 13. The clade 
structure of E. faecium is depicted in figure 2. This figure also illustrates that clade A1 strains are 
predominantly isolated from infections 11. 
 
Figure 2: Clade structure of E. faecium. The origins of the strains and the dates for the split between the clades are 
indicated (ya, years ago). The infectivity score reflects the number of strains of a particular ST isolated from infection. 
Clades are color-coded: clade B in dark blue, clade A1 in red, and clade A2 in gray. The tree is based on alignments of 
DNA sequences of 1,344 single-copy core genes in 73 E. faecium genomes. Reprinted with permission, modified from 
mBio 11.  
  
Most recent phylogenetic reconstruction of whole genome sequenced E. faecium strains, describing 





	   	  
confirmed the relation of the nosocomial clade A1 and commensal clade B. But it found that the 
former A2 clade now appeared as a polyphyletic group in between clade A1 and B, and was 
therefore designated IG (intermediate group). IG is a multiclonal group comprising of clinical, 
animal, and community isolates and its topology varies significantly from the ladder-like topology 
of clade A1. However, as described earlier for A1 and A2, A1 and IG are closely related. 14 
Especially nosocomial E. faecium strains have a highly malleable genome and the capacity to 
acquire and exchange large amounts of DNA. The hospital-associated clade A1 differs from the 
commensal clade by its larger core genome and also has a larger overall average genome size. 
Additionally, MGEs (mobile genetic elements), including plasmids, integrated phages and genomic 
islands, are enriched in clade A1 11. The high gene acquisition of clade A1 is likely to be promoted 
by its tendency to lack functional CRISPR (clustered regularly interspaced short palindromic 
repeats), a bacterial defense system giving immunity against incoming DNA, which would 
normally restrict the acquisition of novel genes 15–17. Further characteristics of clade A1 strains are 
typically the possession of insertion element IS16 18, pathogenicity islands and plasmids or genes 
associated with antimicrobial resistance as well as colonization and virulence 19.  
 
Horizontal	  Gene	  Transfer	  and	  its	  Agents	  
Horizontal	  Gene	  Transfer	  Mechanisms	  	  
HGT (horizontal gene transfer) enables bacteria to disseminate genes among related and unrelated 
bacterial species, which is important for the adaption to new niches or challenges such as 
antimicrobial pressure 11. First studies on transferable antimicrobial resistance in enterococci date 
back to the 1970s 20. Enterococci have a highly plastic genome and especially nosocomial clade A1 
strains harbor multiple MGEs (on average 5 plasmids/ genome in clade A1, compared to 2 
plasmids/ genome in clade B strains; 2 phages/ genome in clade A1, compared to 1 phage/ genome 
in clade B strains; 36 kb of island-associated sequence/ genome, compared to 17 kb of island-
associated sequence/ genome in clade B strains) 11. Importantly, enterococci have been shown to 
transfer resistance traits also to other more pathogenic species, such as S. aureus 21–23.  
Genes, including those encoded by MGEs, are transferred horizontally in various ways and the 
three main mechanisms are transformation, transduction, and conjugation. Resistance genes or other 





	   	  
	  
Figure 3: Main mechanisms of HGT between bacteria. A) Transformation occurs when naked DNA is released by 
an organism and taken up by another organism. A gene, encoding a resistance determinant or a virulence factor (red) 
can get integrated into a plasmid or the chromosome of the recipient. B) If genes are transferred by phages, the process 
is called transduction. C) Conjugation occurs by direct contact between two bacteria, which here is shown to exchange a 
plasmid. Transposons (yellow) can change location within the chromosome and plasmids. Reprinted with permission 
from Nat. Rev. Microbiol. 24.  
 
Transformation is the uptake of naked DNA from the environment by a competent cell 24, but for 
enterococci natural transformation has never been reported 25.  
Transduction, which describes bacteriophage-mediated transfer of DNA from a donor to a recipient 
cell, is only beginning to be reported in enterococci. Bacteriophages may transfer bacterial genes, 
including resistance determinants, due to excision immediately adjacent to the integrated prophage, 
known as specialized transduction, or by packaging of any genomic DNA during their assembly, 
known as generalized transduction 26. Enterococcal phages have the capacity to mediate inter-
species transfer of antimicrobial resistance genes 27 and even whole plasmids can be transferred 
through generalized transduction 28. 
Conjugation, the cell-cell contact dependent exchange of DNA between two live cells, is the 





	   	  
tight regulation of the process 29. Regulators register internal and external signals, such as 
environmental conditions, recipient availability and host cell physiology to initiate the process of 
conjugation. Subsequently, tra genes, which by default are off, are expressed. The tra genes are 
genes necessary for DNA transmission; they encode components of the T4SS (type 4 secretion 
system) as well as DNA transfer and replication 29.  
The ssDNA transfer machinery of Gram-positive bacteria is seen as a minimized version of the 
T4SS found in Gram-negative bacteria. The differences arise from differences in cell wall 
architecture. In Gram-positive bacteria the T4SS spans only one membrane but needs a 
peptidoglycan hydrolase for local digestion of the cell wall. To substitute the lack of sex pili in the 
T4SS of Gram-positive bacteria, cell-cell contact formation involves adhesin-mediated 
condensation of extracellular DNA 30.  
As illustrated in figure 4, mobilizable plasmids code only for a MOB (mobility) module consisting 
of an oriT (origin of transfer), a relaxase, and need a T4SS of a co-resident conjugative system to 
become transmissible. Conjugative or self-transmissible plasmids encode this T4SS in addition to 
the MOB module and a T4CP (type 4 coupling protein). After the establishment of cell-cell contact 
through pili, a T4SS channel is formed and a rolling circle type replication or theta replication 
proceeds. The relaxase cleaves a specific site within oriT to initiate conjugation and a DNA strand 
bound to the relaxase protein is displaced by ongoing DNA replication. The relaxase interacts with 
the T4CP and other components of the T4SS and gets transported to the recipient cell, with the 
ssDNA (single stranded DNA) bound to it. Subsequently, the ssDNA is pumped into the recipient 
by the ATPase activity of the T4CP and finally double stranded DNA is reconstituted in both 
cells 31.  
 
Figure 4: Scheme of transmissible plasmids and essential interactions during conjugation. Conjugative plasmids 
code for the four components of a conjugative apparatus: an oriT (violet), a relaxase (R, red), a type IV coupling protein 





	   	  
Besides these three main mechanisms of HGT, genetic material can also be transmitted through 
nanotubes and membrane vesicles (MV). Nanotubes have structures similar to cell membranes and 
can transfer intracellular molecules including metabolites, proteins, toxins, RNA, and plasmid DNA 
between neighboring and distant bacteria of the same and different genera 32,33. Nanotubes have 
potential for a broad distribution of genes involved in antimicrobial resistance 34. RNA and DNA 
containing MVs also mediate HGT in response to environmental stimuli 35. MVs may spread 
antimicrobial resistance genes such as a carbapenem-resistance gene of Acinetobacter baumannii 36 
and a ciprofloxacin-resistance gene of mycoplasma 37. Also MVs of Gram-positive bacteria contain 
DNA and transfer it between bacteria. Clostridium perfringens MVs contain toxin-encoding genes 
and MVs from Ruminococcus sp. transfer chromosomal DNA in heterogeneous bacterial 
communities 38. Even though it has not been described yet, it stands to reason that nanotube or MV-
mediated HGT mechanisms might exist in enterococci as well.  
 
Mobile	  Genetic	  Elements	  in	  E.	  faecium	  
MGEs are agents of both intra- and intercellular DNA mobility. They can contain genes to replicate 
independently of the chromosome, recombine homologously or non-homologously, as well as to 
move DNA between cells. The MGEs accessory genes typically provide selective advantages to 
their host, for example genes encoding virulence factors or antimicrobial resistance determinants.  
Plasmids	  
Plasmids are semi-autonomously replicating extra-chromosomal genetic elements of modular 
structure. Enterococcal plasmids range in size from 3 kb to above 300 kb and are present in low or 
high copy number, up to more than 20 copies per cell 25,39. The backbone of a plasmid includes the 
genetic modules encoding self-replication and copy number control, and may also encode genetic 
modules involved in stable inheritance and the ability to transfer in between bacteria. Between these 
backbone modules, accessory plasmid modules are integrated. The accessory content gives rise to 
high genetic variability. 
Differences in plasmid replication genes are used to type and classify plasmids 40. Out of 20 
replicon classes defined from Gram-positives, eleven classes have been identified in enterococci. 
Those eleven classes can be divided into four families: RepA_N family plasmids encode replication 
initiators with the RepA_N domain in their N-terminus, Inc18 family plasmids have initiator 
proteins related to the traditional Inc18 group, RCR family plasmids are a large group of plasmids 





	   	  
conserved domain in plasmid replication initiator proteins 25,41. In E. faecium rep17/pRUM and 
rep20/pLG1–type replicons (RepA_N), rep2/pRE25 (Inc18 family), rep14/EFNP1 (RCR family) and 
rep18/pEF418 (Rep_3 family) dominate 40,42.  
An alternative classification scheme for plasmids is MOB typing, utilizing differences in relaxase 
encoding genes 43. Seven relaxase families have been described, out of which MOBQ, MOBC, 
MOBT (found in conjugative elements), MOBV (found in mobilizable plasmids) and MOBP (found 
in conjugative elements and mobilizable plasmids) are present in enterococci 25.  
Another older system of plasmid classification groups plasmids which fail to co-reside into Inc 
(incompatibility) groups 44, such as the enterococcal-streptococcal Inc18 group plasmids 45. Inc18 
group plasmids, i.e. rep1/pIP501 and rep2/pER25 plasmids, often carry multiple antimicrobial resistance 
genes, and have a broad host range among streptococci, lactococci, staphylococci, and 
enterococci 45. The host range is also used to classify plasmids, examples of narrow host range are 
plasmids of the Rep_3 family 42, such as rep18/pEF418, rep11/pEF1071 and relpCIZ2 plasmids, and plasmids 
of the RepA_N family 41. Pheromone-responsive plasmids are conjugative narrow host range 
plasmids. As the name suggests, their conjugative process is induced upon recognition of a 
pheromone-responsive plasmid-free recipient, such as E. faecalis pAD1, pCF10 and pAM373 46.  
Plasmids conferring resistance to antimicrobial agents are called R-plasmids. In enterococci R-
plasmids largely contribute to glycopeptide, quinupristin-dalfopristin, and high-level 
aminoglycoside resistance 47. To ensure stable inheritance in the absence of antimicrobial selection, 
R-plasmids often harbor plasmid addiction systems, namely toxin-antitoxin systems. R-plasmids 
encode labile anti-toxins and stabile toxins, which kill daughter cells that did not inherit the plasmid 
encoding these features 47. rep20/pLG1 plasmids are associated with the axe-txe locus, a plasmid 
stabilizing toxin-antitoxin system, and carry genes involved in antimicrobial resistance 39,42,48.  
Especially in nosocomial E. faecium large conjugative plasmids (above 150 kb) are common, and 
besides antimicrobial resistance related genes 49 may carry genes involved in colonization of the 
gastrointestinal tract 50 among others. They are referred to as megaplasmids and have been reported 
to belong to the rep20/pLG1 type 39. Plasmids can furthermore help the transfer of other MGEs and 
with that serve as scribbling pads in formation and propagation of new operons 51. 
Transposable	  Elements	  
Transposable elements are movable units of DNA. The simplest transposable elements are IS 
(insertion sequence) elements, which encode only enzymes for their own transposition. Typical 
transposable elements with additional genes found in enterococci are composite transposons, Tn3 





	   	  
of IS elements from the same family, which move the DNA in between them. Enterococcal high-
level gentamicin resistance is associated with composite transposons (Tn4001 (Tn5281) and 
variants 52–54, Tn5384 55, Tn5385 56, Tn924 57). High-level glycopeptide resistance encoded by vanA 
in enterococci is associated with a Tn3 family transposon, namely Tn1546 58. Tn3 family 
transposons contain a transposase (tnpA) and a resolvase (tnpR) and move in a replicative fashion. 
Conjugative transposons encode all information for their own excision, conjugation, and 
integration, and were therefore later classified as integrative conjugative elements (ICE). 
Conjugative transposons have for example been associated with resistance to tetracycline (Tn916-
like transposons encoding tet(M) 59) or vancomycin (Tn1549-like transposons encoding vanB2 60). 
Importantly, conjugative transposons may co-transfer other transposons, plasmids, and even large 
chromosomal fragments between strains and they may have a broad host range, like Tn916 61–63. 
Transposable elements, including IS elements, facilitate niche adaptation, contribute to genome 
plasticity and phenotypic variation, as they mediate rearrangements in chromosomal and plasmid 
DNA but also alter expression of genes by disrupting promoters or providing alternative promoters 
or regulators 18,47. Even though newly acquired enterococcal MGEs can pose a severe fitness cost at 
first, this costs can rapidly be reduced and beneficial plasmid-host association may emerge 64. Thus, 
advantages gained through MGEs may outweigh their cost. Even though genetic exchange occurs 
with or without selective pressures, such as antimicrobial treatment, selects for rare events and 
makes HGT more probable 24.  
 
E.	  faecium	  as	  a	  Pathogen	  
Enterococcal	  Infection	  and	  Disease	  	  
In 1899, the term enterococci was introduced to describe a saprophytic intestinal coccus able to 
cause infection 65,66 and the first enterococcal infection, infective endocarditis, was described 67. 
E. faecium infections are typically established upon translocation to the bloodstream, through a 
perturbed intestine or uptake from contaminated hospital environment 68. In the past, the source of 
infection was mainly assumed to be the patient’s own endogenous flora. With the increase of 
nosocomial infections, however, transmission also occurs among patients in a hospital setting 4.  
Today, E. faecium mainly causes urinary tract infections, but also life-threatening infections such as 
bacteremia. Importantly, among the five main bacteremia causing pathogens from 2002 to 2008, the 





	   	  
its major complication is usually the urogenital system, but may also arise from E. faecium intra-
abdominal, pelvic or soft-tissue infections. 4  
Enterococcal infections are most serious in immunocompromised patients, where risk factors 
include diabetes mellitus, transplantation, malignancy, indwelling catheters and chemotherapy 70. 
Another important factor in enterococcal disease is exposure of hospitalized patients to 
antimicrobials against Gram-negative bacteria, which results in substantial changes in the regulation 
of the gut immune system, leading to overgrowth with enterococci 1. Normally, the 
lipopolysaccharide and flagellin of Gram-negative bacteria stimulates the production of REGIIIγ, a 
C-type lectin. REGIIIγ has antimicrobial activity against Gram-positives, including E. faecium. 
Consequently, a decrease in Gram-negatives through antimicrobial exposure will facilitate a down-
regulation of REGIIIγ and thus lead to overgrowth of antimicrobial resistant enterococci 71,72.  
E.	  faecium’s	  Antimicrobial	  Resistance	  and	  Options	  for	  Infection	  Treatment	  
E. faecium has been recognized as one of the ESKAPE pathogens, along with Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species. ESKAPE pathogens cause most nosocomial multi-resistant infections and 
require special attention 73. The first option of treatment for enterococci is mainly ampicillin and 
penicillin 4, but high intrinsic and acquired antimicrobial resistance especially in E. faecium often 
hamper treatment and decrease therapy options. 
Compounds which inhibit cell-wall synthesis are often only bacteriostatic against enterococci 74 and 
E. faecium is intrinsically non-susceptible towards cephalosporins, clindamycin, penicillins, and 
aminoglycosides 1. Additionally, the rate of acquired resistance towards modern antimicrobials in 
E. faecium is high. The main mechanisms of enterococcal antimicrobial resistance are summarized 
in figure 5.  
Approximately 90% of modern nosocomial E. faecium isolates are resistant towards β-lactams. 
PBP5, a penicillin binding protein, is involved in this resistance 1. Besides the low-level intrinsic 
resistance to aminoglycosides, acquired high-level resistance occurs. High-level streptomycin 
resistance is conferred by ribosomal mutations or the acquisition of an aminoglycoside 
nucleotidyltransferase, Ant(3’’)-la or Ant(6’’)-la. The bifunctional aminoglycoside-modifying 
enzyme Aac(6’)-le-Aph(2’’)-la confers high-level resistance to all other aminoglycosides 





	   	  
	  	  
Figure 5: Main mechanisms of enterococcal antimicrobial resistance. The main mechanisms of resistance to β-
lactams (ampicillin), aminoglycosides (gentamycin, streptomycin), glycopeptides (vancomycin), streptogramins 
(quinupristin–dalfopristin), oxazolidinone (linezolid), and lipopeptides (daptomycin) are illustrated. Reprinted with 
permission from Nat. Rev. Microbiol. 1.  
 
Infections caused by β-lactam or aminoglycoside resistant enterococci were usually treated with the 
glycopeptide vancomycin. In 1986, however, the first vancomycin resistant enterococci (VRE) were 
described 75,76. Glycopeptides are cell-wall-active agents, which bind to the D-Ala-D-Ala termini of 
peptidoglycan precursors to inhibit the synthesis of the bacterial cell wall. Glycopeptide resistance 
is achieved, first, through replacing the terminal D-Ala of peptidoglycan precursors with D-Ser, 
resulting in low-level resistance (7-fold vancomycin affinity decrease), or with D-Lac, resulting in 
high-level resistance (1000-fold vancomycin affinity decrease); and second, by removing precursors 
ending in D-Ala-D-Ala 77. Gene clusters, van-clusters, comprising both regulatory and resistance 
genes, encode the determinants conferring vancomycin resistance 78. To date eight genotypic 
variants of acquired vancomycin resistance (vanA, vanB, vanD, vanE, vanG, vanL, vanM, vanN) 
and one type of intrinsic resistance (vanC) have been described in enterococci 77. The vanA, vanB, 
vanD and vanM clusters encode change of the D-Ala-precursor to D-Lac and may cause high-level 
vancomycin resistance, whereas the other van-gene clusters encode change of the D-Ala-precursor 





	   	  
involve the transposition of transposons between different replicons, including plasmids which 
promote horizontal transfer, i.e. in case of vanA 79. The clinically important van-clusters are vanA 
and vanB. Globally and within Europe, vanA is the most prevalent 80, while vanB was the most 
abundant cluster found in Australia previously 81 but also recently increased within Europe 82,83. 
Both clusters are associated with successful MGEs, which may be the reason for their relatively 
high abundance compared to the other van-clusters. vanA is normally part of the Tn3-family 
transposon Tn1546 often found in on conjugative plasmids 84 and vanB is mostly part of the 
integrative conjugative element Tn1549 60, which localizes both on the chromosome and on 
plasmids 84,85. Importantly, VRE bacteremia has a 2.5-fold increase in mortality compared to 
vancomycin-susceptible Enterococcus bacteremia 86.  
In order to treat VRE, quinupristin-dalfopristin, linezolid, and daptomycin are used. However, 
several mechanisms reducing the activity of quinupristin-dalfopristin exist in E. faecium 87,88. Even 
though linezolid resistance still has an overall low prevalence of <1% 89, it is alarming that multiple 
mechanisms of linezolid resistance exist which do not alter the fitness of E. faecium 90. Linezolid 
resistance can be acquired through mutations or gene acquisition, resulting in changes of the 
ribosomal target or efflux, but also cell wall thickness and biofilm formation are under discussion as 
resistance mechanisms (under submission 91). Daptomycin resistance is associated with structural 
changes of the cell envelope and involves mutations in multiple intrinsic genes (under 
submission 91). With this, resistance even to the last resort antimicrobial agents is found in 
enterococci.  
As discussed above, enterococcal infections are therapeutically challenging, due to the intrinsic 
resistance towards many antimicrobial agents, and the ability to acquire resistance towards 
essentially every antimicrobial agent used against enterococci. Therefore, combination therapy of 
synergistic agents is often the only treatment option 92. This approach has its limitations as well, 
since multi-resistances may rule out combination possibilities and toxic side effects are likely to 
occur 1. Thus, novel approaches to treat enterococcal infections are needed. 
Persistence	  and	  Biofilm	  Formation	  
Another factor, which makes E. faecium a resilient bacterium, is its ability to withstand harsh 
conditions. Optimal growth of enterococci is typically at 35°C, but their growth range is as wide as 
from 10 to 45°C 93. Enterococci can also endure both hypotonic and hypertonic conditions 94. 
Normally, enterococci grow in 6.5% NaCl but tolerate higher salt concentrations 95. They further 
withstand chlorine and alcohol preparations frequently used as disinfectants 96,97. Therefore, 





	   	  
hospital surfaces. For example, three CC17 isolates survived for more than 5 years in an in vitro 
setting without nutrition 98; and the same multi-resistant high-risk clone caused infections in a 
Norwegian hospital one year apart from each other, and must have survived within the hospital 
during that time 90.  
Biofilms enhance the resilience of enterococci further, both ex vivo, such as on medical devices and 
in the hospital environment, as well as in vivo, where biofilms are protecting their inhabitants 99. 
Biofilm formation is by definition the adherence of planktonic bacteria to each other and a surface, 
and the subsequent growth resulting in a structured community, often enclosed in an extracellular 
polymeric substance matrix. Biofilm production is regulated by environmental signals such as 
nutrients, pH, temperature, and presence of serum 99. A number of enterococcal genetic 
determinants playing a role in biofilm formation and maturation have been identified, mostly in 
E. faecalis. Among those are surface adhesins, autolysins and glycolipides, which mainly act early 
in the adhesion phase, as well as polysaccharides, extracellular DNA, and proteases, which 
predominate in biofilm maturation 100. Once a biofilm is established, bacteria within biofilms can 
resist phagocytosis, which makes it extremely difficult for the host to clear the bacteria 99. 
Additionally, biofilms protect the bacteria against antimicrobials: 10-1000 times higher antibiotic 
concentrations can be tolerated by a biofilm compared to the amount required to kill planktonic 
bacteria 101. Biofilms are also hot spots for HGT, including exchange of antimicrobial resistance 
genes 102.  
Physical removal of infected medical devices or the infected tissue is usually the only option to 
attack biofilms. So far, the development of anti-biofilm compounds mainly addressed the 
prevention of biofilm formation on medical devices, but to date, there are no drugs available to 
disassemble a biofilm 100. 
Virulence	  Factors	  of	  E.	  faecium	  	  
Generally, E. faecium displays low levels of virulence and pathogenicity. However, due to its 
emergence as a nosocomial pathogen, further knowledge on virulence factors is warranted. Figure 6 
summarizes the current knowledge on E. faecium’s virulence factors.  
Except for virulence factors per se, cell wall components, such as capsular polysaccharides, LTA 
(lipoteichoic acid) and WTA (wall teichoic acid) play a role in virulence of Gram-positive bacteria. 
Together they contribute to phagocytosis-, complement- and antimicrobial-resistance, biofilm 
formation and host or surface attachment, as well as being important immunogenic components 103.   
Colonization and binding to ECM (extracellular matrix) proteins is crucial for the establishment of 





	   	  
and adhesion. E. faecium virulence factors encompass both secreted components and cell surface 
associated factors (reviewed in Gao et al. 103, figure 6).  
Secreted virulence factors comprise cytolysin Cyl, secreted antigen SagA, and gelatinase GelE. Cyl, 
as a haemolysin, damages various host cells, such as red blood cells, neutrophils and 
macrophages 104. SagA, notably the most abundant protein in enterococcal biofilms, contributes to 
colonization by binding to ECM proteins 14,105,106. GelE affects adherence and biofilm formation 107.  
Cell surface-associated virulence factors contribute to phagocytosis–resistance, biofilm formation 
and adhesion to both the host and surfaces. Especially important for adhesion are ECM binding 
virulence factors, such as the collagen adhesins Acm 108,109, Scm 110 and CcpA 111,112, as well as the 
fibronectin/ fibrinogen-binding proteins Fnm 113 and PrpA 114. Cell surface exposure and collagen 
binding of Acm is influenced by the major autolysin AtlA 115. Further cell wall-associated adhesins 
are SgrA 116, EcbA 116 and CapD 117, where the latter is a capsular polysaccharide protein which is 
involved in the immune evasion. The pilus proteins PilA2 118, PilB/ Ebpfm (Pilus) 119 are associated 
with clinical strains and promote biofilm formation. The most widespread virulence factor in 
clinical E. faecium strains is the enterococcal surface protein Esp 103, which besides cell adhesion 
and biofilm formation 120 also contributes to the attachment to silicon-based surfaces 121. 
Additionally, mannose family phosphotransferase systems (PTSclin) are enriched in the clinical 
linage and have been associated with E. faecium virulence 122,123. The transmembrane proteins of 
the PTS phosphorylate carbohydrates, that are translocated across the bacterial cell membrane 122. 
PTS is therefore proposed to be involved in the adaption of the carbohydrate metabolism to 
intestinal colonization 122. As part of another putative PTS the permease BepA was described to be 
involved in endocarditis and biofilm formation in human serum 123.  
Besides interacting with the host through virulence factors, enterococci have to compete with other 
bacteria within the gastrointestinal tract. Therefore, enterococci may utilize bacteriocins, called 
more specifically enterocins, which are peptidic toxins inhibiting the growth of other bacteria, 
including pathogenic microorganisms. For example enterocin P (EntP) inhibits the growth of the 
pathogens Listeria monocytogenes, S. aureus, C. perfringens, and C. botulinum 124. Enterocins are 
mainly plasmid encoded and further include EntA, EntB, EntL50 125, EntQ 126, Bac32 84 and 
Bac43 127. Because of the increasing antimicrobial resistance, bacteriocins gained attention since 






	   	  
	  
Figure 6: Overview of E. faecium virulence factors. Virulence factors utilized by E. faecium are illustrated and 
described in short; including cell wall components, secreted virulence factors and membrane-bound virulence factors. 





	   	  
Immune	  Response	  Towards	  E.	  faecium	  
A mechanical barrier that is virtually impermeable to pathogens is built by epithelial surfaces, 
consisting of epithelial cells joined by tight junctions and the removal of pathogens from surfaces is 
supported by desquamation of skin epithelium or movement due to peristalsis or cilia. In addition, 
chemical factors prevent bacterial growth, such as the low pH of gastric secretions or antimicrobial 
peptides 129. Pathogens, which overcome physical and chemical barriers, encounter cells of the 
innate immune system, the host’s primary defense against microbial attacks, which mediates 
bacterial clearance and bridges to adaptive immunity.  
Innate immunity is induced upon recognition of highly conserved microbial structures, called 
PAMPs (pathogen associated molecular patterns), by PRRs (pattern recognition receptors). Among 
PRRs TLRs (Toll-like receptors) are dominant 130. 
Out of the 10 human TLRs, TLR2 has a central role in the recognition of Gram-positive bacteria, as 
it recognizes peptidoglycan, lipoteichoic acid and lipoproteins. E. faecium is recognized by 
TLR2 131, a receptor expressed by various cells, including neutrophils, macrophages, and dendritic 
cells. CD14 functions as a co-receptor of TLR2 to recognize lipoteichoic acid and has also been 
shown to be involved in the TLR2-recognition of E. faecium. The dimerization partner determines 
the ligand specificity of TLR2 131. The formation of TLR1-TLR2 is induced by Gram-negative 
triacyl-lipopeptides; while TLR2-TLR6 formation is induced by Gram-positive diacyl-
lipopeptides 132. In a mice peritonitis model, early host defense against E. faecium was driven by 
TLR2-dependent signaling via MyD88 (myeloid differentiation primary-response gene 88) resulting 
in NFκB (nuclear factor-κB) activation and expression of proinflammatory mediators 131,133.  
Subsequent, peritoneal macrophages 134, neutrophil influx 135 and opsonization of E. faecium by the 
complement 136 are important in the early immune response of the host. 
The complement system consists of over 30 serum and cell-surface proteins. Its activation occurs 
through three different pathways, all of which lead to the cleavage of the complement component 
C3. In the classical and lectin pathway, induced by antigen-antibody interaction or recognition of 
carbohydrate structures, C3 is cleaved by the C4b2a. In the alternative pathway, which amplifies the 
two other pathways, C3bBb cleaves C3. This cleavage results in the release of the soluble 
anaphylatoxin C3a, attracting phagocytes, and the deposition of C3b and iC3b on the surface of the 
bacterium. C3b and iC3b, in turn, are ligands for cellular receptors on leukocytes, phagocytosing 
the labeled bacterium. Cleavage of C3 also results in the formation of MAC (membrane attack 





	   	  
The thick cell wall of Gram-positive bacteria, including enterococci, is generally thought to prevent 
complement-mediated MAC lysis. However, commensal E. faecium strains have recently been 
shown to be susceptible to a serum phospholipase whereas clinical strains were resistant 140. In 
clinical strains, genes involved in carbohydrate metabolism and nucleotide biosynthesis are 
essential for growth in human serum 141.  
Both complement and antibodies play an especially important role in phagocyte recruitment, and 
thus clearance of enterococci 142–144. Opsonization by the complement also enhances phagocytosis 
by neutrophils and macrophages, the cells first encountered by the bacteria during infection 136. 
Upon endocytosis of a pathogen and subsequent phagosome-formation, the phagosome fuses with a 
lysosome to form a phagolysosome, in which the pathogen is killed 145. However, certain 
enterococcal strains are able to survive even within phagocytes 146–148 and might thereby spread 
systemically 149.  
 
Bacterial	  TIR-­‐domain	  Containing	  Proteins	  as	  Immune	  Evasion	  Factors	  
Recognition	  of	  Bacteria	  by	  the	  Human	  Innate	  Immunity	  and	  TIR-­‐domain	  Signaling	  
As mentioned above, the host innate immune system provides the primary defense against 
microbial attacks and is induced, when PRRs, among them TLRs, recognize PAMPs. PAMP-TLR 
interaction consequently leads to the recruitment of adaptor molecules, whose stimulation results in 
pro-inflammatory mediator expression 150,151.  
The cytosolic side of TLRs and their adaptors all contain TIR (Toll/interleukin-1 receptor)-domains, 
through which homotypic interactions are mediated 152, illustrated in figure 7.  
The five TLR adaptor molecules are MyD88, MAL (MyD88-adaptor-like protein), TRIF (TIR-
domain containing adaptor protein inducing interferon-β), TRAM (TRIF-related adaptor molecule) 
and SARM (sterile α- and armadillo-motif-containing protein). The universal adaptor MyD88 
interacts with all TLRs, except for TLR3, while MAL and TRAM act as bridging adaptors. MAL 
recruits MyD88, and TRAM recruits TRIF. SARM, by contrast, is not recruited to TIR-domains to 
initiate signaling like the other four adaptors but inhibits TRIF-dependent signaling 152. The TLR-
adaptors couple to protein kinase pathways, leading to activation of transcription factors such as 
NFκB, as well as members of the IRF (interferon-regulatory factor) family, which in turn induce 
inflammatory cytokines and co-stimulatory molecules. This results in an host-mediated immune 





	   	  
 
Figure 7: TIR-domains are mediating the interaction between TLRs and their adaptors. TLR complexes 
recognize various ligands (green-colors) and utilize each adaptor (blue-colors) differently, with exception of SARM, 
which is negatively interfering with TRIF and TRAM. All TIR-domains are colored in grey. Based on O’Neill et al. 152.  
 
TIR-­‐domains	  as	  Conserved	  Modules	  in	  Different	  Organisms	  	  
Originally defined as the cytoplasmic domain of TLRs 154, the TIR-domain is a protein-protein 
interaction domain of approximately 125-200 amino acids. It is widely distributed among different 
species, including animal, plants, and bacteria. TIR-domains function through self-association or 
interact homotypic with other TIR-domains to build up protein scaffolds for the formation of 
protein complexes, especially immune signaling complexes.  
The TIR-domain typically adopts a flavodoxin-like fold built up by a central five-stranded parallel 
β-sheet (βA- βE) surrounded by five α-helices (αA- αE) and connected by flexible loops, which are 
named based on the secondary structures they connect 155, as illustrated in figure 8. Despite the low 
sequence identity among TIR-domains, the core fold of the TIR-domain is conserved 156. The loops 
and helical regions, create differences in the structure of the TIR-domain among the TIR-containing 
proteins. This variability is assumed to be responsible for the specificity required for protein-protein 
interaction and signaling. Especially the BB loop (connecting strand βB and helix αB) and DD loop 
(connecting strand βD and helix αD) of the TIR-domains are important for TIR-TIR 
interaction 155,157 
Within the TIR-domains the sequence motifs, named box 1, box 2 and box 3, are found 156. Box 1 
corresponds to the βA strand, and maintains structural stability of the TIR-domain, for example in 
TLR2 158. Box 2 corresponds to the βB strand and the BB loop, and box 3 corresponds to the αE 





	   	  
species found that boxes 2 and 3 are rather poorly conserved and that other regions are also of 
functional importance 156,159,160.  
 
Figure 8: Illustration of TIR domain structures. On the left, a cartoon representation of the MyD88 TIR-domain 
crystal structure is shown, labeled with key secondary structure elements. The five parallel β-strands are colored orange, 
the rest cyan. On the right, the MyD88 structure (cyan) is superposed to the structures of the TIR-domains from TLR2 
(lime), TLR1 (pale green), and Paracoccus sp. PdTLP (magenta). Reprinted with permission from Proc. Natl. Acad. 
Sci. U.S.A. 161.  
Interference	  with	  TLR	  Signaling	  by	  Bacterial	  TIR-­‐domain	  Containing	  Proteins	  
TLR signaling provides an interesting point of vantage to pathogens, because of the TLR’s front-
line role in innate immunity initiation. Counteraction of this initial recognition may be conducted by 
bacteria through molecular mimicry of key structures, such as TIR-domains 162. TIR-domains are 
widespread among bacteria, suggesting that they function as general protein-protein interaction 
domains, which may adopt diverse uses 163. The TIR-domain is located in the N- or C-terminal 
region of the protein and the remaining protein domains can vary 156.  
The first study identifying bacterial TIR-homologues found more than 200 TIR-domain proteins in 
a wide range of both Gram-negative and Gram-positive species, including the pathogens Salmonella 
enterica and S. aureus 164. 
Most studies on bacterial TIR-proteins explored their role as putative virulence factors interfering 
with host signaling, especially NFκB activation. The putative mode of action of bacterial TIR-
domain containing proteins, illustrated in figure 9, is competition with adaptor molecules164–167 or 
degradation of adaptor molecules 168. However, the specific targets of most bacterial TIR-domain 
containing proteins have not been identified. 
The first functionally characterized bacterial TIR-domain containing proteins, S. enterica serovar 
Enteritidis TlpA, was shown to impair TLR- and MyD88-dependent activation of NFκB when TlpA 
was expressed in the eukaryotic cytoplasm. Additionally, a tlpA deletion mutant was attenuated in 





	   	  
	  
Figure 9: Bacterial TIR-domain containing proteins negatively interfere with innate immune recognition. Left) 
Bacteria are recognized by TLRs (light red), which subsequently interact with adaptor molecules (blue) via TIR-TIR 
interactions. Signaling cascades are induced leading to the activation of transcription factors (TF, such as NFκB), which 
results in phagocytosis of the bacteria and consequently the induction of an inflammatory response and microbial 
killing. Right) Bacteria with the gene encoding TIR-domain containing proteins (dark red), express and release those 
proteins. The bacterial TIR-domain containing proteins interfere with TLR-adaptor signaling and thus the bacterium 
evades the innate immune response. All TIR-domains are illustrated in grey.  
 
In line with these observations, Brucella TcpB and Escherichia coli TcpC were shown to interact 
with MyD88 and studies with their respective deletion mutants found them to play a role in 
pathogenesis 165. Similar observations were also made for the Gram-negative Yersinia pestis YpTdp 
169 and Paracoccus denitrificans PdTlp 166 as well as for the Gram-positive S. aureus TirS 167 and 
E. faecalis TcpF 170,171. 
How bacterial TIR-domain containing proteins are released has not been finally resolved, but stands 
to reason, that these proteins are secreted, even though most of them lack a signal-peptide. Studies 
in E. coli TcpC 161 and S. aureus TirS 167 showed, that no bacterium-cell contact is required for the 
virulence factor to exert its function.  
Genes encoding TIR-domain containing proteins often localize in regions of phage origin, examples 
of this are tlpA 164, tcpC and tcpB 165. It is therefore likely that tir-genes are disseminated through 
lateral gene transfer. Additionally, the staphylococcal tirS-gene localizes within SCC 
(staphylococcal chromosomal cassette), a mobile genetic element containing a fusC gene conferring 
fusidic acid resistance 172. The fact that sub-inhibitory concentration of fusidic acid increase TirS 





	   	  
Besides their role as virulence factors in pathogens, TIR-domain proteins were also identified in 
non-pathogenic bacteria as well as fungi and archaea 163, and showed functions deviating from the 
common theme. For example, the two staphylococcal TIR-proteins, SaTlp1 and SaTlp2, found in 
zoonotic ST398, up-regulated NFκB signaling instead of down-regulating it 173. Therefore it has 
been suggested that TIR-domains are general protein-protein interaction domains, which are not 
primarily virulence factors but were secondarily adapted to host mimicry and immune evasion 163.  
 
Extracellular	  Vesicles	  
Extracellular	  Vesicles	  Exist	  in	  All	  Domains	  of	  Life	  
EVs (extracellular vesicles) are spheres of lipid-bilayer enclosing liquids, formed from membranes 
either in a physiological process or upon mechanical disruption of membranes. Whether EVs are 
artifacts of lipid-self-assembly and released during cell death or whether vesiculation is an actual 
physiological process was subject of continuing debates. Nevertheless, multiple studies report that 
an active metabolism is required for the EV-production and that killed cells do not produce EVs 174. 
This underlines that the observed EVs are due to a physiological process. EVs are found in all 
domains of life investigated till this day, including eukaryotes, archaea, and bacteria, suggesting a 
universal phenomenon 175. As a common theme, vesicles can bud directly from the membrane of 
organisms without cell wall but have to escape the cell wall barrier in cell-walled organisms 174. 
EV-release provides an additional mode of secretion, which gives the flexibility to respond to 
environmental cues, especially in inter-microbial and host-microbe interaction 175.  
Archaeal	  Vesicles	  
The evolutionary most basic process of vesicle production is probably represented by archeal 
membrane vesicles, which combine features found in both eukaryotic and bacterial vesicle 
production. Archeal membrane vesicles are surface derived and released through budding of the cell 
surface. They play a role in inter-microbial communication and genetic exchange. For example, the 
90-230 nm sized Sulfolobus derived vesicles contain toxins, sulfolobicins, which inhibit the growth 
of competing species 176, and Thermococcales derived membrane vesicles contain DNA and hence 
might mediate gene transfer 177. 
Eukaryotic	  Vesicles	  	  
Eukaryotic cells, including animal, fungal and plant cells, release vesicles of at least three types 





	   	  
blebbing during programmed cell death. They are the most heterogeneous and biggest extracellular 
vesicles with a size of 1000-5000 nm. The second type, shedding microvesicles are 100-1000 nm in 
size and directly bud from the cell surface. The third type, exosomes with a size of 40-100 nm are 
derived from multivesicular bodies within the cell and then released 178.  
Originally it was thought, that animal cell-derived exosomes are part of a cellular waste disposal 
system. However, recently it was found that they mediate intercellular communication, modulate 
immune responses and shuttle nucleic acids 179. Since exosomes are released by all types of human 
cells and are found in all body fluids, a variety of therapeutic and diagnostic purposes has been 
suggested for exosomes, such as cancer diagnostics, targeted drug delivery and immunotherapy 179.  
The eukaryotic parasite Leishmania donovani releases extracellular vesicles containing up to 98% 
proteins without a secretion signal, among them putative virulence factors 180. This underlines the 
importance of vesicles as an alternative secretion tool for eukaryotic cells.  
Since fungi possess a cell wall, an open question is how fungal vesicles transit this barrier. It has 
been hypothesized, that vesicles escape through pores, in areas where the cell wall is thinned, which 
happens for instance during daughter cell budding, or by remodeling the cell wall through 
enzymes 174. Similar to other eukaryotic microbes, fungal vesicles may be utilized by pathogens to 
release virulence-associated components. For example, virulence factors are vesicle-associated in 
the human pathogens Crytococcus neoformans and Candida albicans 181,182. However, virulence is 
unlikely to be the only function of fungal vesicles, since also the non-pathogenic Saccharomyces 
cerevisiae releases vesicles 183.  
Even plant cells were found to release extracellular vesicles, particular upon pathogen infection 184. 
Plant extracellular vesicles may facilitate the export of proteins without secretion signals, required 
for transport through the standard secretory pathway, and contain important defense compounds, 
such as hydrogen peroxide 184. 
Bacterial	  Membrane	  Vesicles	  
In the 1960, the first bacterial vesicles were described in E. coli 185,186, and later in several other 
Gram-negative species including Shigella sp. 187, Salmonella sp. 188, and Vibrio sp. 189. In Gram-
negative bacteria, vesicles derive from the outer membrane and are therefore called OMVs (outer-
membrane vesicles). They contain outer membrane components but also inner membrane 
constituents and cytoplasmic elements. Even though vesiculation has been studied intensively in 
Gram-negative bacteria, attempts to generate a mutant deficient in OMV production failed, 
indicating that vesiculation is only partially under genetic regulation and additionally dependent on 





	   	  
surface, its disruption impacts OMV release. A model to explain vesiculation, especially in only 
partially hydrated environments is that nanopods are formed to release vesicles 190. The most recent 
model to describe OMV biogenesis in hydrated environments is based on phospholipid 
accumulation in the outer leaflet of the outer membrane, whereupon vesicles pinch off from the 
outer membrane 191. In addition to conventional one-bilayer OMVs, a second less abundant two-
bilayer vesicle type, so-called outer-inner membrane vesicles (O-IMVs), was described, first in the 
Antarctic bacterium Shewanella vesiculosa 192 and then also in Gram-negative pathogens 193–195. O-
IMVs are formed when both plasma and outer membrane stretch out into the extracellular milieu 
and pull cytoplasmic content in the vesicle. O-IMVs can therefore contain cytoplasmic proteins and 
DNA 193. 
OMVs derived from pathogens have been shown to be involved in bacterial virulence, by exerting 
functions such as delivery of biomolecules, including toxins, biofilm formation, adherence to the 
host and stress response 196. In non-pathogenic bacteria, OMVs play roles similar to other 
extracellular vesicles, such as cellular communication, surface modification and clearance of 
unwanted molecules 175.  
In the past, the existence of MVs was out of question in Gram-positive bacteria, based on the fact 
that vesicular escape was precluded by the thick cell wall of these bacteria. Nevertheless, nowadays 
studies are exploring the field of MVs derived from Gram-positive bacteria 174. The composition 
and cargo of both Gram-negative and Gram-positive vesicles are illustrated in figure 10.  
 
	  
Figure 10: Model of the predicted composition of vesicles from Gram-negative and Gram-positive bacteria. The 
differences in cell wall architecture of Gram-negative and Gram-positive bacteria cause differences in vesicluar 
composition as well. Gram-negative OMVs are typically surrounded by the outer membrane and contain periplasmic 
proteins. Gram-positive MVs, on the contrary, carry cytoplasmic components and are encased by the cytoplasmic 






	   	  
The first reports of Gram-positive derived MVs in Bacillus cereus and Bacillus subtilis 198 dates 
back as far as the 1990s. However, these studies were not regarded for the next 20 years until MVs 
were described in 2009 in S. aureus 199 and since then gained increased attention 174.  
Data on the genetic regulation of MV biogenesis is still warranted. Also, how MVs escape the 
Gram-positive cell wall has not been conclusively clarified. However, similar to mechanisms 
suggested for fungal cell wall transit 174, cell wall modification might be involved in MV release. 
For example, S. aureus-derived MVs contain peptidoglycan-degrading enzymes, which can alter the 
cell wall structure 199. Another recently proposed mechanism is phage-triggered vesiculogenesis, 
where phage endolysins locally digest the cell wall to form holes through which the cytoplasmic 
membrane can stretch into the extracellular space to form vesicles 200.  
A wide range of cargo reflecting the cellular content has been associated with MVs from Gram-
positive, including DNA, proteins and lipids. For example in C. perfringens, it was shown that 
DNA within MVs was protected from exonucleases 201. This implies that DNA is protected from 
eventually harsh environmental conditions and may be transported over long distances and thus, 
MVs might play a role in gene transfer. The cargo of MVs is also associated with drug resistance, 
an example of this are S. aureus-derived MVs containing a penicillin-binding protein 202. MVs can 
also act as vehicles for antimicrobial resistance-conferring proteins, for instance, S. aureus-derived 
MVs deliver β-lactamase proteins to ampicillin-susceptible bacteria which make them resistant to β-
lactams 203. Additionally, MVs may contain proteins which are important in immune system 
evasion and bacterial pathogenesis, such as virulence factors and toxins 174. MVs may furthermore 
be key players in host-pathogen interactions, as they cause disease without the living bacterial 







	   	  
Objective	  
	  
The overall aim of this PhD project was to investigate determinants contributing to virulence of 
nosocomial E. faecium. These include virulence factors, membrane vesicles as possible means of 
conveyance of these factors, and megaplasmids harboring virulence traits.  
 
The specific objectives of Paper I are  
1) To explore the epidemiology and genetic context of ORFs encoding TIR-domain 
containing proteins in E. faecium;  
2) To evaluate of the role of TIR-domain containing proteins in bacterial virulence through 
functional studies; and  
3) To study whether TIR-domain containing proteins in E. faecium are secreted and 
whether they may be associated with membrane vesicles.  
 
The specific objectives of Paper II are 
1) To detect MVs derived from clinically relevant E. faecium and describe their 
morphology; as well as  
2) To characterize the proteinaceous content of E. faecium derived MVs.  
 
The specific objectives of Paper III are 
1) To describe the genetic content of a megaplasmid originating from an E. faecium blood 
culture isolate and characterize traits contributing to bacterial virulence; and 
2) To investigate the prevalence of these traits in the E. faecium population and their 
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Choice	  of	  Methods	  
	  
In general, the aim of research is to create reproducible and sustainable knowledge. Thus, methods, 
which meet the requirements of the modern scientific principles and deliver trustworthy data, are to 
be chosen. Different approaches illustrating the same phenomenon should be combined and the 
experimental design kept as simple as possible. Once a hypothesis is formulated, other explanations 
should still be taken into consideration. The methods should, therefore, be chosen to shine light on 
the research question from different angles. Still, every method will have its inevitable limitations, 
which have to be kept in mind when interpreting the data.  
 
Virulence	  Factor	  Research	  
Prediction	  of	  Virulence	  Factors	  Using	  Computational	  Methods	  
The identification and subsequent characterization of virulence factors are important to understand 
the mechanisms underlying bacterial virulence as well as to identify novel points of intervention 
such as drug and vaccine targets. With the growing mass of available data on genome and protein 
sequences generated in the postgenomic age, it is an important first step to identify and describe 
virulence factors and other proteins of unknown function on their sequence information. Thereafter 
this information may be used to guide the way for experimental design of functional assays in the 
laboratory. The choice of in silico methods to predict virulence factors may be challenging, as 
platforms or data may be incomplete. Thus multiple approaches should be combined to validate or 
discard the initial finding. 
The first bacterial TIR-domain containing proteins were found by detecting domains in silico and 
subsequent characterization 164. In this study, we choose a similar approach, where two putative 
E. faecium proteins annotated with a TIR-domain were identified in the protein database at NCBI 
and characterized using computational methods regarding properties such as protein family, 
secretion signals, and structure. Similar methods were also used to investigate the open reading 
frames adjacent of the identified TIR-domain containing proteins.  
After virulence factor identification it should be kept in mind that predicted domains and functions 
are still only predicted. Therefore, epidemiological and functional approaches, which were guided 
by the results of the in silico predictions, were included in the presented study. 
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Epidemiology	  of	  Virulence	  Factors	  
An epidemiological approach was used to assess the distribution of the identified virulence factors 
among E. faecium isolates of different origin. This strategy will show whether the virulence factor 
is rare or common and in what kind of isolates it is present. If a virulence factor-encoding gene is 
unique to a certain kind of isolate it can accordingly serve as an isolate-specific marker.  
In this study, a combination of PCR screenings and WGS (whole genome sequencing) was used. On 
one hand, PCR might give a false negative result, for example, if the DNA was degraded, or the 
reaction does not work and depends on the utilized primers. Still, PCR is very simple, cheap and 
fast. WGS, on the other hand, is more time and resource intensive. However, it gives not only 
information about the presence of a gene, but the data can be further used to explore the genetic 
context of the gene and build phylogenetic trees. This is particularly interesting when looking at 
clonal expansion and transmission events. In the past, MLST-typing and PCRs were used, however, 
it recently becomes more and more apparent, that MLST typing is not reliable in E. faecium, 
because of the high recombination frequency in this bacterium 206. Phylogenic trees can be 
especially interesting tools to study the emergence and spread of a virulence factor. From this data, 
one might speculate what kind of selective pressure lead to events in the evolution of a virulence 
factor.  
Functional	  Characterization	  of	  Putative	  Virulence	  Factors 
For functional studies, a combination of methods based on the purified virulence factor and 
methods comparing the characteristics of the wild-type and its isogenic mutant are used as 
complementary approaches.  
The advantage of using purified recombinant proteins is, that the system allows for tight control. 
Additionally, purified recombinant proteins are used to generate antibodies, which are useful tools 
to detect the protein. However, the purification of a virulence factor might be challenging and many 
previous studies failed to purify full-length bacterial TIR-domain containing proteins. The 
disadvantage of systems using purified proteins is that the conditions of choice might be less 
physiological than other systems. Still, in combination with other – more physiological – systems, 
studies of the purified protein can provide important information.  
In order to evaluate the immune evasive properties of a putative virulence factor, two main 
approaches are typically used. In the first approach, eukaryotic cells are transfected with an 
eukaryotic expression plasmid encoding the bacterial immune evasion factor to study its 
interference with the host intracellular signaling. When a receptor of the eukaryotic cell is now 
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stimulated it can be evaluated whether ectopic expression of the immune evasion factor interferes 
with the signaling of the receptor 116. In the second approach, the purified immune evasion factor is 
added to the host cells. Thereafter the receptor is stimulated and again it is evaluated whether the 
virulence factor interferes with the signaling of the receptor 141. For both approaches, the evaluation 
whether the virulence factor interferes with the signaling of the receptor can be done through a 
luciferase assay or by measuring the cytokines in the cell culture supernatant. In order to perform a 
luciferase assay the cells have to be transfected with another plasmid encoding a luciferase under 
NFκB control. When the receptors signaling now results in NFκB production, the luciferase is 
transcribed and can be quantified 167,207. 
In this study, the second approach, where the purified protein is added to the cell culture, was used 
since proteins expressed in bacteria are more likely to have the correct conformation and we 
furthermore speculated that the virulence factors would be released by the bacterium and taken up 
by the cell. Whether the protein interferes with the receptor signaling was assessed by measuring 
cytokines in the supernatant, since cytokine release is a result of stimuli. 
An isogenic mutant, lacking the virulence factor-encoding genes was created to compare it to the 
wild type and describe the phenotypic manifestation of the absence of the virulence factor. 
E. faecium is known to be difficult to manipulate genetically 208. In highly genetic unstable 
organisms such as E. faecium the generation of knockouts can be challenging, i.e. the deletion of 
only one gene or also the generation of complementary strains might be biologically impossible. 
Especially in those organisms, it should be verified that no mutations occur in the process; therefore 
the generated isogenic mutant was sequenced. The assays in which the isogenic mutant and the wild 
type were compared were chosen to represent challenges E. faecium would be likely to face upon 
infection, such as serum deposition, phagocytosis, and intracellular survival.  
To prove the importance of a virulence factor in bacterial infection, mouse infection models are 
mostly warranted. However, nosocomial E. faecium are well adapted to the human host and even in 
humans act as rather opportunistic pathogens, which only cause disease under certain preconditions, 
such as immunodeficiency. Thus, it is questionable how well a mouse infection model could 
represent the situation under which E. faecium would cause human infection and how much can be 
extrapolated from a mouse model. 208 
Therefore fresh human blood was used as the model of choice in this study. Still, also this model 
does not take into account the pre-adaption E. faecium might undergo during the transition from the 
intestine or the environment to the bloodstream. However, the blood survival model represents the 
environment E. faecium would encounter upon infection rather closely.  
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Studying	  Membrane	  Vesicles	  
Isolation	  of	  Vesicles	  and	  Their	  Morphological	  Characterization	  
Vesicular research was hampered in its very beginning because it was thought that observed 
vesicle-like structures were only cellular debris. Even after the description of OMVs in Gram-
negative bacteria, the scientific community precluded the existence of MVs in Gram-positive 
bacteria based on the assumption that vesicles could not escape a barrier such as the Gram-positive 
cell wall. Now it is known, that living cells are required for vesicle production, and that dead cells 
did not produce vesicles, showing that vesiculation is a physiological process 174.  
However, there is still no standardized protocol for the preparation of a pure vesicle sample. Based 
on observation in different bacterial species it is likely that the method needs optimization for every 
bacterial strain and the chosen method should be verified using different methods for every 
preparation to ensure the desired quality 209. A typical workflow of MV preparation is shown in 
figure 11. The isolation of MVs from different E. faecium strains was performed based on an 
isolation method described previously for the Gram-positive S. aureus 210,211. First, a bacterial 
culture is obtained under the desired growth conditions, from which then the supernatant is 
sterilized through filtration. Second, the bacteria-free supernatant is concentrated in centrifugal 
filters with a size cut off at 100 kDa and third, the concentrate is ultracentrifuged to pellet MVs.  
At this stage, the vesicular pellet may be contaminated with proteins, pili or phages. Therefore, a 
purification step using density gradient centrifugation is included. The density gradient medium of 
choice is OptiPrep, an iodixanol based solution. OptiPrep was shown to be superior to other density 
gradient solutions since it prevents damage of frail membranous structures 212.	  The vesicle sample is 
mixed with a high-density solution and transferred to the bottom of an ultracentrifuge tube and 
overlaid with step gradients of low-density solutions. The vesicles have a lower density then cell 
debris due to their lipid content. Thus, during centrifugation, the vesicles migrate to a layer 
according to their density and form a ring. The fractions are then collected and the density gradient 
medium may be exchanged to PBS. Another approach is top loading, where the vesicle sample is 
placed on top of the last low-density solution. During the cause of this study also top loading was 
tested, but bottom loading gave the best results for the purification of E. faecium MVs. We 
experienced that with bottom loading contaminating proteins and cell debris stay in the bottom of 
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Typically, the quality and the properties of the MV sample and the properties of MVs are assessed 
through visualization and content analysis. This is done using transmission electron microscopy, 
which allows the characterization of the MVs sizes, shapes, and overall appearance. Moreover, this 
method will assess the purity of the sample, regarding non-MV material such as protein aggregates, 
phages or pilis. As a complementary approach, atomic force microscopy was conducted to visualize 
the release of MVs by the bacterium to the environment. This technique provides a three-
dimensional surface profile, and MVs may be seen next to the bacterium. Furthermore, the size 
distribution, as well as the membrane potential, was measured. Additionally, lipid staining and 
immunoassay for the presence of peptidoglycan, the key cell wall component, were performed.  
	  
Figure 11: Typical MV preparation workflow. First, bacteria are cultured in liquid media (Medium composition, 
harvesting time point, and stress condition may be varied). Second, bacteria are removed by sterile filtration. Third, the 
culture supernatant is concentrated. Fourth, MVs are purified according to the required purity. Reprinted with 
permission from Microbiol. Res. 213.  
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Identification	  of	  Vesicle-­‐associated	  Proteins	  in	  Mass	  Spectrometry	  
MV-associated proteins were identified by means of mass spectrometry. This is done through 
sample digestion and fractionation prior to introduction in a mass spectrometer. The experimentally 
obtained fragmentation spectra are matched with a database for identification. This database 
contains simulated spectra generated through in silico digestion of protein sequences extrapolated 
from DNA sequences. There are a few alternative approaches, such as protein purification followed 
by residue-by residue sequencing. However, this approach is not feasible at proteome level. 
Moreover, one should be aware that mass spectrometry holds its limitation regarding protein 
digestion and peptide-matching algorithm 214. In addition, it should be taken into account that the 
databases are being generated from a specific DNA sequence 214. The whole genome sequence of 
each E. faecium strain itself was used as database for the respective sample to include all strain-
unique proteins. The mass spectrometry obtained data was used in a descriptive way to characterize 
MV-associated proteins.  
Different computational tools were used to describe the localization origin and the amount of 
secreted MV-associated proteins. The combination of different tools allowed comparison and 
validation of the data obtained by each individual approach. Further analysis of MV-associated 
proteins included searching for known virulence factors, vaccine candidates, and antimicrobial 
resistance determinants. It should be noted that merely the presence of a protein with a certain 
ascribed function does not necessarily translate to the protein executing that function in the context 
it was found. Due to the above-mentioned challenges and limitations, the MV study in E. faecium 
was kept descriptive. However, functional studies are warranted to describe the physiological role 
of enterococcal MVs.  
 
Investigating	  the	  Genetic	  Content	  of	  Megaplasmids	  
Identification	  of	  Megaplasmid-­‐Encoded	  Factors	  Contributing	  to	  Virulence	  	  
Since the goal of this research was to identify factors, which contribute to the virulence of 
E. faecium, the contents of a megaplasmid from a blood culture isolate was investigated.  
Factors other than antimicrobial resistance determinants were suggested to be involved in 
enterococcal gastrointestinal colonization, and genes encoding these factors were located on a 
megaplasmid 50. Transferable megaplasmids larger than 145 kb harboring the hylEfm-gene, named 
after a putative glycosyl hydrolase, were shown to promote virulence in peritonitis 215, but the 
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hylEfm-gene itself was found not to be involved in this effect 216. Thus, it was suggested that the 
plasmid content should be investigated for other virulence promoting factors.  
Initially, megaplasmids of nosocomial E. faecium strains were sequenced and putative secreted 
proteins, including hypothetical secreted proteins, were selected for further analysis. The hypothesis 
was that secreted megaplasmid-encoded factors could interfere with the host’s immune defense and 
enable E. faecium to invade the host. The software SignalP was used to predict putative secretion 
signals encoded by the ORFs. RT-PCR was then used to assess whether these putative secretory 
factors are transcribed. Furthermore, their prevalence in nosocomial versus commensal strains was 
investigated by screening through PCR. A set of more than ten putative secretory factors, which 
were expressed and found in blood culture isolates, was heterologously expressed in E. coli without 
the secretion signal and successfully purified. The purified proteins were tested, one at a time, in a 
wide range of immune evasion assays, including binding to leucocytes, complement evasion, serum 
killing, red blood cell lysis and phagocytosis assays. However, none of the recombinant proteins 
showed an activity in these assays (unpublished results), and we hence choose to examine the whole 
megaplasmid in a more biologically relevant setting.  
Therefore, it was investigated whether the megaplasmid could be transferred into a plasmid-free 
strain and enhance its survival in human blood. Exposing the bacteria to whole human blood was 
used to mimic the environment E. faecium would be facing during bacteremia, one of the most 
serious enterococcal infections. The megaplasmid from a bacteremia isolate (K60-39) was therefore 
transferred into other strains. The first transfer was done into a plasmid-free laboratory strain, which 
has been used in previous mating experiments (BM4105-RF 217). The plasmid was additionally 
transferred into a plasmid-free community isolate (E1007 140), which was previously shown to be 
serum susceptible 140. Different transconjugants resulted from the mating and comparing them in a 
blood survival assay gave us the possibility to identify factors, which contribute to the blood 
survival advantages.  
Characterization	  of	  Virulence	  Determinants	  in	  Megaplasmids	  
To find a function of putative virulence factors, an often-used strategy is to purify the candidate 
protein and test it in a multitude of immune evasion assays, as mentioned above. For example, 
putative virulence factors could bind to blood cells and thus hinder bacterial recognition, play a role 
in complement evasion, interfere with serum killing, hinder phagocytosis and/or help bacterial 
intracellular survival.  
However, the heterologous expression and purification of putative virulence factors may be difficult 
or in some cases even impossible and thus rule out the characterization of certain proteins. 
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Furthermore, these assays are mainly used to test one protein at a time and it is therefore difficult to 
examine proteins, which function as multimers or act together in a biological pathway. Another 
limitation is, that evasion assays are designed based on previously described phenomena but might 
not be able to detect novel functions.  
Since the putative virulence factor candidates did not show a function in any of the immune evasion 
assays, we therefore choose to use bioinformatic tools to describe factors putatively contributing to 
E. faecium survival in blood.  
The transconjugants were sequenced and comparison of the ones replicating in human blood and 
the plasmid, which did not promote survival, revealed a list of putative blood survival promoting 
factors. These factors were then bioinformatically characterized and screened for in the NCBI 
database. Based on these data, hypotheses could be constructed on how these factors might aid 
bacterial survival. Still, functional studies would be warranted to conclude their mechanism of 
action.  
To assemble the chromosome and plasmids of the original donor, it was sequenced using PacBio, a 
long-read high-quality technique. A hybrid sequencing approach was used to describe the genomic 
contents of the transconjugants. At first, the transconjugants were sequenced using Illumina, a very 
accurate sequencing technique that produces short reads. At a second stage, the transconjugants 
were sequenced using Oxford Nanopore Technology. Since enterococci contain numerous long 
repetitive sequences, such as IS elements, the long reads of Nanopore are necessary to pass these 
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Summary	  of	  Main	  Results	  
Paper	  I:	  Enterococcus	  faecium	  TIR-­‐domain	  Genes	  Are	  Part	  of	  a	  Gene	  
Cluster	  Which	  Promotes	  Bacterial	  Survival	  in	  Blood	  
E. faecium TIR-domain containing proteins (TirEs) were identified, and their structure showed a 
typical TIR-fold. The genes encoding them, tirEs, were part of a putative mobile genetic element of 
phage origin exclusive to nosocomial E. faecium isolates.  
TirEs were detected within the bacterial supernatant even though they do not have a signal peptide. 
A novel release mechanism was identified since TirE2 was found within enterococcal membrane 
vesicles.  
The tirE gene cluster did not influence cytokine release, phagocytosis or bacterial survival within 
macrophages. However, the tirE genes were predominant in blood culture isolates, expressed upon 
blood exposure of E. faecium and the tirE gene cluster promoted bacterial proliferation in human 
blood. 
	  
Paper	  II:	  Enterococcus	  faecium	  Produces	  Membrane	  Vesicles	  Containing	  
Virulence	  Factors	  and	  Antimicrobial	  Resistance	  Related	  Proteins	  
Membrane vesicles (MV) were produced by E. faecium. They were spherical in shape, range in size 
from 37±23 nm to 83±29 nm, and were negatively charged. E. faecium derived MVs were 
associated with lipids and peptidoglycan. 
The proteinaceous content and the number of MV-associated proteins depended on strain and 
growth condition, but the overall proteomic pattern regarding the percentage of proteins that 
derived from the core genome, their origin of localization, and whether they had a signal peptide or 
not, was similar among E. faecium derived MVs.  
11 previously known virulence factors were found to be MV-associated. Among them were 
adhesins (CapD, PrpA), collagen binding proteins (Acm, Scm), and fibronectin binding protein 
(Fnm), as well as biofilm promoting factors (AtlA, Esp, SagA). Further, vaccine candidates, as well 
as antimicrobial resistance related proteins, were MV-associated, including all proteins of the vanA-
cluster of a vancomycin-resistant strain.  
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Paper	  III:	  Megaplasmid-­‐encoded	  Metabolic	  Factors	  Enhance	  
Proliferation	  of	  Enterococcus	  faecium	  in	  Human	  Blood	  
A reppLG1-type megaplasmid encoding high-level gentamicin resistance and a T4SS was 
transferrable from a bloodstream isolate via a laboratory strain to a commensal strain. In the 
commensal strain the plasmid conferred a significant increase in bacterial proliferation in human 
blood.  
The genes encoded by this megaplasmid were mainly involved in primary metabolic processes, 
such as carbohydrate metabolism, membrane transport and information processing. The replication 
initiation protein-encoding gene reppLG1 was prevalent in E. faecium of diverse origin, including 
bloodstream as well as commensal isolates. However, the blood proliferation promoting candidate 
genes were significantly enriched among clinical E. faecium isolates. We found indications for 
exchange of gene clusters between plasmid and chromosome, suggesting that megaplasmids serve 
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From a harmless gut commensal, E. faecium has undergone a transition towards a multi-resistant 
nosocomial pathogen, posing a major threat to human health, especially in immunocompromised 
individuals 1,68. Not only does the hardy bacterium survive over prolong periods of time on various 
surfaces 98, resist extreme conditions and even alcohol preparations 96,97 but E. faecium also 
acquires genetic material tremendously fast 11, which enables it to adapt to new selective pressures.  
 
The aim of this thesis was to shed light on virulence-related aspects of nosocomial E. faecium from 
different angles, including virulence factors utilized for immune evasion (Paper I), membrane 
vesicles containing virulence factors amongst other cargo (Paper II) and megaplasmids encoding 
factors aiding E. faecium survival in human blood (Paper III).  
 
In E. faecium the search for new virulence factors might be hampered since the bacterium is 
foremost a commensal and does not natively display high virulence 208. In enterococci, many factors 
contribute to fitness within the human host as well as fitness in other ecological niches. Thus, 
pathogenicity- or fitness-enhancing factors are probably not only virulence factors in a strict sense. 
“Virulence factors” are defined as substances necessary for causing disease in the host, but not 
necessary for survival in other contexts 208. However, determinants, which also play a role in other 
contexts than causing disease, such as metabolic genes, can be important in colonization and/or in 
out-competing other bacteria. It seems that the virulence of enterococci depends on more than a few 
main players, and is likely to depend on strain variable combinations of factors that jointly enhance 
infection 208. Also from the highly plastic and heterogeneous genomes, especially of the nosocomial 
clade 11,14 it is verisimilar that E. faecium does not employ just one winning strategy, but that 
multiple factors aid its adaption to the hospital environment. Our findings reinforce this hypothesis 
since various proteins – resembling metabolic as well as virulence factors – were found to be 
associated with MVs of nosocomial E. faecium (Paper II). Also, the here investigated 
megaplasmids harbor multiple – mainly metabolic – factors (Paper III).  
The prevalence of megaplasmids and their genes promoting proliferation in human blood among 
nosocomial isolates indicates that these metabolism-related genes contribute to the infectious 
phenotype of E. faecium (Paper III). The function of the factors was predicted based on 





	   	  
functional studies would be needed to unravel their specific roles and interplay. The main functions 
of the megaplasmid encoded genes are presumably primary metabolic pathways, especially 
carbohydrate metabolism (Paper III) and it consequently stands to reason that E. faecium has an 
advantage if it can utilize different nutrient sources in the course of infection where it would face 
varying environments. Carbohydrate uptake and metabolism genes are also the genes with the 
largest difference between human commensal and the nonsocial strains 11 and carbohydrate 
utilization has been described as a driver in adaption to niches like a hospital environment and host 
colonization 218,219. A limitation of this study is that we focused on analyzing genes, which are 
present, but it is difficult to conclude on the importance of the absence of genes. It is apparent, that 
smaller plasmids might pose a lower cost and therefore be advantageous. It could also be 
advantageous for the bacterium if genes, which have an adverse effect on blood survival, are lost. A 
description of the exact topology and closing of the plasmids might help to reveal other differences 
between the two transconjugants, which both enhanced proliferation in blood but to varying 
degrees, such as gene synteny and regulation by introduction or removal of mobile elements. 
Furthermore, to generalize these finding, a larger number of megaplasmids would need to be 
investigated, since this study presents foremost a case study of one megaplasmid and the transfer of 
it to the commensal might have been only possible because of the interim laboratory strain (Paper 
III). Still, the findings of this study can guide future work.  
 
Even if it might be difficult to narrow the many facets of E. faecium down to single players, 
virulence factor research is important in order to understand pathogenicity. Here, we describe 
multiple virulence factors to be associated with MVs (Paper II), among them TirEs, which we 
describe as novel virulence factors of E. faecium (Paper I). A strategy to search for virulence 
factors is to predict those with secretion signals, using tools like SignalP or PrediSi, as it is 
anticipated that secreted proteins are more likely to interact with the host. Generally, exported 
proteins are synthesized with an N-terminal signal peptide directing them to the respective transport 
pathway 220. However, if virulence factors, as described here for TirE (Paper I) and other virulence 
factors (Paper II), are found in the bacterial supernatant even though they lack a secretion signal 
peptide and/or packed in MV, one would have to think differently when predicting putative 
virulence factors.  
Since we found that the TirE locus enhances blood survival and purified TirE down-regulated the 
cytokine (IL-8) response (Paper I), we hypothesize that TirE will also interact with the human host 





	   	  
of the TirE locus and we thus could not assign individual functions to the single genes. Besides 
their function as immune evasion proteins, bacterial TIR-domain containing proteins probably also 
have bacterial proteins as interaction partners. They might not necessarily have their primary 
function as agents of subversion since TIR-domains are foremost protein-interaction domains and 
also found in non-pathogenic bacteria 163. Bacterial TIR-domains were for example proposed to be 
involved in nucleic acid binding or as nucleases 221. Recently, an intrinsic NADase activity was 
described in bacterial, mammalian and achaeal TIR-domains and TIR-domain containing proteins 
proposed to influence metabolic and energetic pathways 222. S. aureus TirS degrades NAD+ also in 
mammalian cells, suggesting that its function as virulence factor could be due to its NADase 
activity 222. The precise interaction partner of TirE, of bacterial and/or host origin, remains to be 
identified by future studies. 
 
An important factor in pathogenicity is the ability of virulence factors to spread, both in terms of the 
virulence factor protein itself to reach its target but also virulence encoding genes to other bacteria. 
In enterococci risks arise from HGT because these rather less-pathogenic bacteria are able to 
exchange genes encoding antimicrobial resistance and virulence factors with other microbes 223, 
including more pathogenic bacteria 21–23. For example, MRSA (methicillin-resistant S. aureus) 
became high-level resistant to vancomycin through an E. faecium multiresistance conjugative 
plasmid with Tn1546 harboring vanA resulting in a virtually untreatable VRSA (vancomycin-
resistant S. aureus) 23. Here, we furthermore found that a megaplasmid carrying determinants for 
high-level gentamicin resistance and determinants involved in blood survival is transferable from 
nosocomial E. faecium via a laboratory strain to a commensal E. faecium strain (Paper III). This 
points out the potential of E. faecium to gather and spread resistance and/or virulence genes to both 
pathogens and commensals, increasing the virulence of its cohabitees.  
We found that the genes encoding two TirEs along with the intermediate gene Hp1 and adjacent 
genes are localized on a putative MGE flanked by integrases and is exclusive to clade A, suggesting 
lateral transfer (Paper I). A mobile genetic context is found for other E. faecium virulence factors. 
Genes encoding phage integrase family proteins flank the gene cluster of the carbohydrate 
phosphotransferase system (Pts) which is enriched in clinical strains and absent in commensal 
isolates 122. Furthermore, a putative transposase was found upstream of fmn 113. Except for that, 
none of the other virulence factors of E. faecium were yet described to be associated with putative 
MGEs. Similar to genes encoding TirEs, the virulence factors SgrA, EcbA, PilA and PilB, BepA 





	   	  
different variants in community versus nosocomial isolates. Thus it would be interesting to explore 
the genetic context of these virulence factors to link them to MGEs, since their predominance in the 
nosocomial clade suggests lateral transfer. Subsequently, HGT of E. faecium virulence factors 
localized on putative MGEs should be verified experimentally. We tested the transferability of the 
putative MGE-tirE in a preliminary experiment. We used a strain where tirE was replaced by a 
gentamicin resistance gene as a donor in a filter-mating experiment and plated the transconjugants 
on gentamicin plates. Unfortunately, we could not confirm the transferability of the putative MGE 
(unpublished result), but we speculate that it might need the help of a conjugative plasmid, as was 
previously described for other E. faecium MGEs 224,225. It would hence be worthwhile to test 
mobilization of MGE-TirE and other E. faecium genes encoding virulence factors located on 
putative MGEs by introduction of a conjugative plasmid known to mobilize genes in E. faecium.  
Gene organization of bacterial TIR-containing proteins were previously studied in the closely 
related E. faecalis 170 and in the zoonotic S. aureus ST398 173. In E. faecalis two variants of gene 
arrangement were found: a TIR-domain containing tcpF gene appeared by itself or the tcpF gene 
was intersected by a GTPase 170. However, no functional studies were conducted on the intersected 
variant. In S. aureus ST398 the two genes, saTlp1 and saTlp2, encoding TIR-domain containing 
proteins lie adjacent to each other 173.  
Hp1 is inserted between the two genes encoding E. faecium TIR-containing proteins presented here 
(Paper I). Since we were able to link these genes by RT-PCR, we suggest that they are expressed 
as one operon. BLAST-searches identified Hp1 as a SIR2-like domain-containing protein. These 
proteins have been described as deacetylases 226, but in initial experiments, no deacetylase activity 
was detected (unpublished result). The function of Hp1 thus remains elusive and should be 
investigated in future studies.  
Interestingly a correlation between the lack of hp1 in the tirE-gene cluster and the presence of vanB 
was found (Paper I). In previous studies in German and Polish isolates, hp1 was found to be an 
entry point for the vanB ICE 82,83. This could present a link between virulence factors and 
antimicrobial resistance genes, similar to an MGE of S. aureus. TirS localizes within the MGE 
SCCmec together with genes encoding fusidic acid resistance and exposure to fusidic acid further 
increased the expression of tirS 172. Thus, it would be interesting to investigate in strains lacking 
Hp1 but encoding vanB whether hp1 is an entry site for the vanB ICE and if vancomycin exposure 
has an impact on tirE expression. Moreover, vanB could potentially be mobilized together with tirE, 
as it would localize on a putative MGE if hp1 serves as an entry point, linking two 





	   	  
A novel mode of E. faecium cargo dissemination discovered here are MVs (Paper II). Whether E. 
faecium MVs contain nucleic acids and act as means for HGT, remains to be examined by future 
studies. We investigated the proteinaceous content of MVs from four different clinically relevant 
strains and found both antimicrobial resistance-conferring proteins as well as virulence factors 
associated with the MVs (Paper II). We hence hypothesize that other bacteria in the community 
potentially could utilize these factors. The virulence factors we discovered, however, represent a 
snapshot of what the bacteria release in medium in monoculture, and their contents might be altered 
upon exposure to stressors such as antimicrobials, the presence of a host or competing 
microorganisms.  
The findings of the study on E. faecium MVs are strengthened using four different clinically 
relevant strains in two different growth conditions. This first report of E. faecium MVs was purely 
descriptive, and functional studies are needed to further understand the purpose of MVs for 
E. faecium itself. An active metabolism is required for the MV production, and MVs are created 
through a physiological process rather than being artifacts 174. Still, it is not clear whether 
E. faecium MV release is an active process including sorting mechanisms or mainly whether MVs 
act as a waste disposal system.  
Since we found various proteins to be MV-associated (Paper II), it is likely that enterococcal MVs 
play important roles in bacterial communities similar to other bacterial MVs, for example by 
delivering enzymes to break down extracellular material into nutrients 227 or by acting as decoys for 
bacteriophages or antimicrobial agents in the bacterial immune defense 228. Apart from functions of 
E. faecium MVs in bacterial physiology, their impact on host responses will be an interesting field 
to study, especially for the utilization of MVs as probiotics or vaccines. For example, E. coli OMVs 
have potential as probiotics 229 and this application might also be interesting for E. faecium as they 
normally co-exist as commensals within the human intestine.  
 
While investigating MV-associated proteins, we found previously described vaccine candidates 
(Paper II). In times of increasing antimicrobial resistance vaccines are one of the most promising 
alternatives, since they bear a low risk to develop resistance and are used prophylactically, rather 
than after an infection is established and the host’s health is impaired 230. One might ask whether it 
is a good idea to vaccinate against bacteria such as E. faecium, which mainly co-exist as 
commensals being a beneficial part of the healthy intestinal flora. However, a vaccination should 
mainly prevent bloodstream infections, since IgG antibodies would primarily reside in the blood 





	   	  
candidates exclusive to nosocomial strains and hereby exploit the differences between commensal 
and nosocomial strains. For the previously described vaccine candidates, antibodies against SagA 
mediate opsonic killing in human blood 231, and the two metal binding lipoproteins elicit IgG 
response 232. It is thus likely that MVs containing vaccine candidates would elicit a similar 
response. Capsular polysaccharides, as the previously described vaccine candidates, are often poor 
immunogens, but their immunogenicity can be enhanced by conjugation with a carrier protein 233. If 
the whole vesicle preparation would be used though, the vesicle itself could be the immunogenic 
234. Still, an enterococcal vaccine should be carefully evaluated to rule out that it does not eradicate 
asymptomatic carriage resulting in undesired changes in microflora with unknown future 
consequences. Also, a vaccine would probably be most useful if given only to certain well-defined 
risk groups or on passive immunotherapy since patients at bacteremia risk are likely to have an 
impaired immune response 233.  
 
Other suggested therapeutic uses for MVs include drug-delivery in cancer therapy 235, as antibiotic-
delivery to treat biofilms 236, and alleviation of allergy and mediate immune regulation 237,238. 
Immune regulation could also be an application of bacterial TIR-proteins, which interfere with TLR 
signaling (Paper I). Potential drugs could be designed as a more potent version of bacterial TIR-
proteins and be used in diseases with excessive TLR signaling (e.g. rheumatoid arthritis, systemic 
lupus erythematosus, colitis) 239.  
Even plasmids, which normally are the main players in spread of antimicrobial resistance and 
virulence (Paper III), could bear potential as use for antibacterial treatment and a number of 
approaches have been suggested. Conjugation could be inhibited to prevent the transfer of plasmids 
between bacteria and several relaxase inhibitors have been identified 240–242. To eliminate multi-
resistance plasmids from the bacterial population and resensitizing the bacteria to antimicrobial 
agents, plasmid replication could be inhibited, for example by mimicking plasmid incompatibility 
through small molecules 243. Furthermore, plasmid maintenance systems could be exploited to 
directly and selectively induce death in drug-resistant bacteria 244,245. No compounds based on these 
strategies have made it yet to clinical application but the high prevalence and threat of resistance 
plasmids makes them attractive target points 246 and studying their biology and content will 







	   	  
Conclusion	  
	  
Over the last decades, E. faecium has arisen as a multi-resistant pathogen and research on both 
antimicrobial resistance and virulence of the bacterium has increased. Still, many questions remain 
unsolved and the aim of this thesis was to expand the knowledge on determinants contributing to 
the virulence of nosocomial E. faecium.  
 
The findings of this thesis advanced the field of E. faecium’s virulence in different aspects. First, 
TIR-domain containing proteins, TirEs, of E. faecium are identified and characterized as novel 
virulence factors located on a putative MGE of phage origin and exclusive to nosocomial strains 
(Paper I). Second, membrane vesicles, MVs, are described for the first time in enterococci and 
found to contain varying cargo, including virulence factors, antimicrobial resistance related proteins 
as well as vaccine candidate proteins and thus might play an important role in virulence (Paper II). 
Third, a megaplasmids of nosocomial E. faecium is shown to promote blood survival, presumably 
through genes encoding factors involved in metabolic processes (Paper III).  
 
Our results are in line with previous studies, stating that the nosocomial clade harbors different 
traits from the commensal clade. The described virulence factors, TirEs, are exclusive to 
nosocomial strains (Paper I) and also the megaplasmid-encoded factors promoting blood survival 
are significantly enriched in nosocomial strains (Paper III). With the MVs we identified a novel 
mode of cargo dissemination of E. faecium (Paper II) and this research bears much potential for 
future functional studies, in regards of interaction with the host as well as the bacterial community, 
nutrient acquisition, or antimicrobial resistance.  
 
In the future, this research on the virulence of nosocomial E. faecium will hopefully provide 
valuable groundwork to understand E. faecium’s relationship to the human host and inspire novel 
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